Trials / Completed
CompletedNCT03598751
Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis
An International Multicenter Randomized Double-blind Placebo-controlled Clinical Study of the Efficacy and Safety of Subcutaneous BCD-085 in Patients With Psoriatic Arthritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 194 (actual)
- Sponsor
- Biocad · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study BCD-085-8/PATERA is a multicentre double-blind placebo-controlled Phase 3 study in patients with psoriatic arthritis (PsA). The objective of the study is to evaluate the efficacy and safety of BCD-085 comparing to placebo in patients with PsA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BCD-085 | 120 mg / 2 mL subcutaneously |
| DRUG | Placebo | 2 mL |
Timeline
- Start date
- 2018-07-25
- Primary completion
- 2019-06-26
- Completion
- 2022-08-31
- First posted
- 2018-07-26
- Last updated
- 2025-07-08
Locations
3 sites across 2 countries: Belarus, Russia
Source: ClinicalTrials.gov record NCT03598751. Inclusion in this directory is not an endorsement.